These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 25515865)
1. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia. Vo QA; Lin JK; Tong LM Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Dang CH; Durkalski VL; Nappi JM Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503 [TBL] [Abstract][Full Text] [Related]
3. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390 [TBL] [Abstract][Full Text] [Related]
4. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia. Bain J; Meyer A Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889 [TBL] [Abstract][Full Text] [Related]
5. Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia. Duewell BE; Briski MJ; Feih JT; Rinka JRG; Tawil JN J Pharm Pract; 2021 Aug; 34(4):529-534. PubMed ID: 31645190 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Kiser TH; Burch JC; Klem PM; Hassell KL Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382 [TBL] [Abstract][Full Text] [Related]
7. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. Joseph L; Casanegra AI; Dhariwal M; Smith MA; Raju MG; Militello MA; Gomes MP; Gornik HL; Bartholomew JR J Thromb Haemost; 2014 Jul; 12(7):1044-53. PubMed ID: 24766902 [TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Kiser TH; Jung R; MacLaren R; Fish DN Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293 [TBL] [Abstract][Full Text] [Related]
10. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. Sun Z; Lan X; Li S; Zhao H; Tang Z; Xi Y Int J Hematol; 2017 Oct; 106(4):476-483. PubMed ID: 28600720 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia. Kennedy K; Steinke D; King S; Poe K; Reeves J; Short M Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):262-8. PubMed ID: 21902659 [TBL] [Abstract][Full Text] [Related]
13. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Levine RL; Hursting MJ; McCollum D Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006 [TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors. Cooper T; White CL; Taber D; Uber WE; Kokko H; Mazur J Am J Health Syst Pharm; 2012 Nov; 69(22):1993-8. PubMed ID: 23135566 [TBL] [Abstract][Full Text] [Related]
15. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113 [TBL] [Abstract][Full Text] [Related]
16. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Kiser TH; Fish DN Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502 [TBL] [Abstract][Full Text] [Related]
19. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Tsu LV; Dager WE Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825 [TBL] [Abstract][Full Text] [Related]
20. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. Guzzi LM; McCollum DA; Hursting MJ J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]